Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XP+Samfenet in Advanced Gastric Cancer
NCT04309578Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- Mar 2020
- Primary completion
- Jul 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in gastric cancer (GC) and gastroesophageal junction cancer, sponsored by Asan Medical Center. Primary endpoint: Overall Response Rate at 2 years. Started Mar 2020; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT04309578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04309578.